A
074430
vs
K
KOSPI 200
Over the past 12 months, Aminologics Co Ltd has underperformed KOSPI 200, delivering a return of +9% compared to KOSPI 200's +142% growth.
Stocks Performance
074430 vs KOSPI 200
Performance Gap
074430 vs KOSPI 200
Performance By Year
074430 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Aminologics Co Ltd
Glance View
Aminologics Co Ltd is a South Korean biotech company focused on developing peptide-based drug candidates. In simple terms, it tries to turn short chains of amino acids into medicines that can treat specific diseases, rather than selling everyday consumer health products. Its main work is research and development, not large-scale manufacturing or retail sales. The company’s customers are usually other drug makers, research partners, or institutions that need early-stage drug technology. Aminologics can make money by doing contract research, licensing its technology, or partnering on the development of its drug candidates. That means its value comes from owning and advancing scientific know-how that bigger pharmaceutical companies may want to use. What makes this business model different is that it sits near the start of the pharmaceutical value chain. Instead of selling finished medicines directly to patients, it builds drug ideas and platform technology that can be handed off, co-developed, or licensed out. That makes the company more dependent on scientific progress, patent protection, and partnerships than on traditional product sales.
